Micronutrients II: Water-Soluble Vitamins & Trace Elements

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review. Only sources actually returned by the tool are cited; no trust scores are invented. Note: dedicated vitamin B12/cobalamin queries initially returned a reproducible server error (HTTP 500), later traced to a backend schema bug that rejects sources tagged evidence_level: case_report (a level B12 topics frequently surface). Re-querying with review/systematic-review-oriented phrasing and smaller result sets avoided case-report sources and returned valid data; the B12 content below is now grounded in both those incidental folate/homocysteine sources and dedicated B12 sources [38][39][40][41].

---

1. Introduction

Water-soluble vitamins and trace elements are the workhorses of intermediary metabolism — cofactors for hundreds of enzymes, rarely stored in meaningful reserve, so deficiency develops fast and presents distinctively. Most cannot be "banked" for months: thiamine stores last ~2–3 weeks, vitamin C weeks to months, and even B12, the outlier with years of hepatic storage, depends on an absorption pathway with multiple failure points. This module surveys the B-vitamin complex (folate, B12, B6, thiamine, niacin), vitamin C, and the trace elements iron, iodine, zinc, selenium, and copper, emphasizing the symmetry of harm: for nearly every nutrient here, both deficiency and excess produce disease, and several flagship supplementation trials have failed or backfired.

This is high-yield clinical material. Deficiencies cluster in specific populations — bariatric-surgery patients, chronic PPI and metformin users, alcohol-use-disorder patients, strict vegans, the institutionalized elderly, and malabsorptive/inflammatory GI disease — with board- and bedside-relevant presentations (macrocytic anemia, peripheral neuropathy, cardiomyopathy, goiter). Equally important: plausible mechanisms and epidemiologic associations (folate and cancer, selenium and prostate cancer, homocysteine and cardiovascular disease) have repeatedly failed to translate into supplementation benefit in randomized trials — a pattern to internalize before reflexively recommending a pill.

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Describe the biochemical role of folate and B12 in one-carbon metabolism, and explain the mechanistic basis for neural-tube-defect prevention and the folate–B12 masking phenomenon.
2. Enumerate the major causes of B12 and folate deficiency (malabsorption, drugs, dietary restriction) and their distinct hematologic and neurologic presentations.
3. Explain the pathophysiology of thiamine deficiency (Wernicke-Korsakoff syndrome) and refeeding syndrome, and state the evidence-based prevention protocol.
4. Describe the mechanisms of scurvy and vitamin C's antioxidant/cofactor roles, and critically appraise the evidence for high-dose and intravenous vitamin C in infection, cancer, and sepsis.
5. Explain heme versus non-heme iron absorption, hepcidin-mediated regulation, and the clinical spectrum from iron deficiency anemia to hereditary hemochromatosis.
6. Describe iodine, zinc, selenium, and copper physiology, their deficiency and toxicity syndromes, and the evidence (including major failed or mixed trials — SELECT, AIM-HIGH, HPS2-THRIVE) for and against supplementation.
7. Critically appraise homocysteine-lowering B-vitamin trials for cardiovascular and cognitive endpoints, distinguishing biomarker change from hard clinical outcomes.

3. Scientific Foundations

3.1 One-carbon metabolism: folate and B12

Folate and B12 converge on one-carbon metabolism (OCM), supplying methyl groups for nucleotide synthesis and remethylating homocysteine to methionine via B12-dependent methionine synthase [1][21]. Deficiency of either raises homocysteine and slows nucleotide synthesis in embryonic tissue — why periconceptional folic acid prevents neural tube defects (NTDs): each 100 ng/mL rise in maternal RBC folate cuts spontaneous pregnancy loss ~8%, and parental RBC folate ≥400 ng/mL cuts it 64% [21]. Maternal B12 <200 pg/mL similarly raises NTD risk, and choline/betaine offer a parallel homocysteine-clearing route [1][20]. Combining homocysteine with MTHFR genotype and nutrient status is proposed to improve pregnancy-risk stratification [34]. Clinically important: the folate–B12 masking phenomenon — high-dose folic acid corrects B12-deficiency anemia but not its demyelination, letting neurologic injury progress silently [1][21].

3.2 Vitamin B12: absorption, deficiency etiologies, and presentation

B12 absorption requires gastric-acid release from food protein, binding by haptocorrin, transfer to intrinsic factor (parietal cells), and receptor-mediated uptake in the terminal ileum; a minor IF-independent passive-diffusion route (~1% of dose) underlies high-dose oral therapy [39]. This explains the classic etiologies: autoimmune intrinsic-factor loss (pernicious anemia), reduced acid from chronic PPI/H2-blocker use, metformin — which disrupts the calcium-dependent binding of the B12–IF complex to its ileal receptor (partly reversible with calcium) — ileal disease/resection, and strict vegan diets, since B12 is essentially absent from plant foods [39][40]. Deficiency causes macrocytic anemia with hypersegmented neutrophils, but its more feared feature is neurologic injury — subacute combined degeneration, neuropathy, cognitive change — mechanistically driven by loss of methylmalonyl-CoA mutase activity, MMA accumulation, and destabilized myelin; it can precede anemia and may not fully reverse if treatment is delayed, hence checking B12 before empiric folate [1][20][40]. Because serum total B12 is insensitive in the borderline range (~180–350 pg/mL), holotranscobalamin ("active B12," the earliest depletion marker) and methylmalonic acid (the most sensitive/specific functional marker, though elevated in renal dysfunction and modifiable by gut-microbial propionate) better detect cellular deficiency, especially in vegans and older adults [38][41]. AllNutrition dedicated-B12 query evidence_strength: moderate, consensus_level: moderate.

3.3 Folate, fortification, and the homocysteine–cancer controversy

Mandatory folic-acid fortification sharply reduced NTDs but raised a genuine cancer-risk controversy. Dietary folate is fairly consistently linked to reduced GI (colorectal, pancreatic) cancer risk, while synthetic folic-acid supplements show null effects, implying dose/food-matrix context matters [32]. B12–cancer evidence is mixed and site-specific, with a possible positive association with esophageal adenocarcinoma [32]. Periconceptional folate exposure also measurably shifts the DNA methylome in leukemia case-control data — a reminder of epigenetic reach beyond hematology [10].

3.4 Thiamine: Wernicke-Korsakoff syndrome and refeeding syndrome

Thiamine (B1) cofactors pyruvate dehydrogenase, transketolase, and α-ketoglutarate dehydrogenase, gating carbohydrate entry into oxidative metabolism. Since neurons depend on oxidative phosphorylation, deficiency causes cerebral energy failure — lactic acidosis, Na⁺/K⁺-ATPase failure, calcium-driven neuronal death in the mammillary bodies — producing Wernicke-Korsakoff syndrome (ophthalmoplegia, ataxia, confusion) [23]. Chronic alcohol use and severe malnutrition are the dominant risk factors [23]. Clinically decisive: IV dextrose in a thiamine-depleted patient consumes remaining thiamine and can precipitate Wernicke's, hence thiamine before or with glucose [23]. The same mechanism scales up in refeeding syndrome, where refeeding-driven insulin release pulls phosphate, potassium, and magnesium into cells, producing severe deficits compounded by thiamine depletion [15][2]. Prevention: start nutrition at 40–50% of goal, advance over 3–4 days, give thiamine 100–300 mg/day for 5–10 days before feeding, monitor electrolytes, and favor enteral over parenteral nutrition [2][15].

3.5 Vitamin B6 and niacin

Pyridoxine (B6), as PLP, cofactors >160 reactions including GABA and homocysteine metabolism [11]. Deficiency causes dermatitis, glossitis, and seizures; chronic high-dose supplementation causes peripheral sensory neuropathy, the basis for a ~100 mg/day upper limit [11]. B6 shows the most consistent inverse observational GI-cancer association among B-vitamins [32].

Niacin (B3), the NAD/NADP precursor, causes pellagra (dermatitis, dementia, diarrhea, death) when deficient [22]. Pharmacologic niacin improves lipids but is a case study in surrogate-outcome failure: AIM-HIGH stopped early for futility and HPS2-THRIVE found no added cardiovascular benefit over statins, with hepatic insulin resistance and a stroke trend in AIM-HIGH [14][22].

3.6 Vitamin C: scurvy, antioxidant function, and the IV controversy

Ascorbic acid cofactors prolyl/lysyl hydroxylase, stabilizing collagen; deficiency (scurvy) causes capillary fragility and poor wound healing, preventable at ~10 mg/day, though RDAs (75–90 mg/day) target broader antioxidant sufficiency [26]. As the principal water-soluble antioxidant it neutralizes ROS, though at high concentration with free iron it can turn pro-oxidant via Fenton chemistry [26]. High-dose/IV vitamin C shows evidence heterogeneity well: regular ≥1,000 mg/day modestly shortens colds and cuts severe-symptom duration ~26%, without reliably preventing colds [30][26]. In sepsis, trials are discordant — CITRIS-ALI showed reduced mortality without improving SOFA/CRP, while VITAMINS and ACTS showed no benefit; a meta-analysis called the signal hypothesis-generating, possibly concentrated in a 3–4 day window [25]. Oral antioxidants for cancer prevention have been disappointing, while IV ascorbate as a radio/chemotherapy adjunct remains experimental [22][29].

3.7 Iron: absorption, hepcidin, deficiency, and overload

Heme iron absorbs ~15–35% versus 2–20% for non-heme iron, which needs acid-dependent reduction to Fe²⁺ [24]. Hepcidin governs balance by degrading ferroportin, the only iron exporter, rising with sufficiency or inflammation to cause "functional deficiency" in chronic disease, and blunting a second oral dose's absorption within 24 hours — the basis for alternate-day dosing [24]. Iron deficiency anemia is treated with oral ferrous sulfate (~60 mg elemental, which outperformed lactoferrin in an RCT [17]; food-based and supplemental interventions similarly improve iron status in at-risk active females [4]) or IV iron (ferric carboxymaltose/iron isomaltoside, comparably effective head-to-head [28]) for malabsorption or heart failure, where trials improved exercise capacity though not always mortality [24]. Iron overload (hemochromatosis, typically HFE C282Y) reflects hepcidin/ferroportin dysregulation; unchecked iron drives Fenton-reaction stress and ferroptosis, causing cirrhosis, cardiomyopathy, and "bronze diabetes," managed with phlebotomy or chelation [16].

3.8 Iodine: deficiency and excess

Iodine is incorporated into T4/T3. Deficiency raises TSH, driving compensatory goiter, tracked via urinary iodine (adequate 100–199 µg/L) and goiter prevalence [33][9]. Selenium, iron, and zinc co-support hormone synthesis, so combined deficiencies compound dysfunction [9][13]. Excess iodine (kelp, amiodarone, contrast) triggers the Wolff-Chaikoff effect; most escape within days, but susceptible individuals develop persistent hypothyroidism, while iodine-deficient/nodular thyroids can instead develop hyperthyroidism (Jod-Basedow phenomenon) [33]. Thyroid function is also nutrient-sensitive beyond iodine itself: obesity/overnutrition independently impairs thyroid hormone biosynthesis and utilization, reversible with weight loss [6].

3.9 Zinc, selenium, and copper

Zinc maintains epithelial barrier integrity and T-cell/IL-2 function; deficiency is common in vegans, the elderly, and chronic disease, raising infection risk [1][31]. Supplementation reduces pediatric diarrhea duration and may modestly help colds and COVID-19 outcomes, not pneumonia [1][31]. Low zinc/high phytate intake independently associates with iron-deficiency anemia in children [5]. Chronic high-dose zinc causes zinc-induced copper deficiency, presenting as cytopenia (85–93% of cases), amplified by age ≥70, female sex, and CKD [36].

Selenium is essential for glutathione peroxidase; severe deficiency causes Keshan disease, an endemic cardiomyopathy now understood as threshold-driven [27][3]. It follows a U-shaped curve (RDA 55 µg/day; ~10× that risks selenosis). The SELECT trial (200 µg/day in already-replete men) found no prostate-cancer benefit and increased diabetes risk, consistent with broader reviews of nutrition and prostate cancer showing early promise for selenium giving way to null or harmful large-trial results — supplementing beyond sufficiency caused net harm [3][27][35].

Copper homeostasis depends on ATP7B-mediated biliary excretion, and dietary copper deficiency itself disrupts colonic barrier integrity and promotes inflammation in preclinical models [7]. Wilson disease (ATP7B loss-of-function) causes toxic copper accumulation with Kayser-Fleischer rings, diagnosed by low ceruloplasmin with high urinary/hepatic copper, treated with chelation or zinc [19][30]. Acquired copper deficiency most often follows zinc-induced competition for absorption, mimicking primary hematologic disease [36][19].

3.10 Homocysteine-lowering B-vitamin trials: surrogate versus hard outcomes

Combined folate/B12/B6 therapy reliably lowers homocysteine and vascular stenosis, but a CHD meta-analysis found no reduction in cardiovascular events or mortality [8], consistent with homocysteine being a marker rather than a modifiable cause [8][37]. Cognition is more encouraging but narrower: homocysteine >11 µmol/L raises dementia risk 1.15–2.5-fold, and B-vitamin therapy slows decline specifically in MCI with elevated baseline homocysteine, with no benefit — possibly harm — when homocysteine is normal [18]. This dissociation between biomarker change and hard-outcome benefit is a clear lesson on why surrogate endpoints cannot substitute for outcome trials.

4. Clinical Relevance

This module's nutrients account for common, consequential deficiencies: iron deficiency anemia in menstruating women and GI-bleeding patients; B12 deficiency in the elderly, long-term metformin/PPI users, post-bariatric-surgery patients, and vegans; thiamine deficiency in alcohol-use disorder and any malnourished or refeeding patient; and iodine or selenium deficiency in restrictive or geographically unusual diets. Equally, clinicians must resist reflexive supplementation: high-dose niacin, selenium, and IV vitamin C carried seductive mechanistic stories that failed rigorous outcome trials, and zinc, iron, and selenium megadosing cause real iatrogenic disease. The unifying skill is targeted, diagnosis-driven supplementation — replace a documented deficiency to a defined target, not "more is always better."

5. Evidence Review

Established (high confidence):

• Periconceptional folic acid prevents neural tube defects; folate/B12/homocysteine are functional OCM-adequacy markers in pregnancy. evidence_strength: moderate, consensus_level: moderate [1][21][20].
• Thiamine deficiency causes Wernicke-Korsakoff via cerebral energy failure; glucose before thiamine can precipitate it; thiamine prevents refeeding syndrome. evidence_strength: moderate, consensus: moderate [23][15][2].
• Heme iron is more bioavailable than non-heme; hepcidin governs absorption via ferroportin degradation; oral and IV iron both effectively treat iron deficiency anemia. evidence_strength: strong, consensus: moderate [24][17].
• Combined B-vitamin therapy lowers homocysteine and vascular stenosis but does not reduce cardiovascular events or mortality. evidence_strength: strong, consensus: moderate [8].
• Niacin (AIM-HIGH, HPS2-THRIVE) improves lipids but adds no CV outcome benefit to statins. evidence_strength: moderate, consensus: moderate [14][22].
• SELECT: selenium supplementation in replete men gave no prostate-cancer benefit and increased type 2 diabetes risk. evidence_strength: strong, consensus: moderate [12][27].

Probable:

• B-vitamin therapy slows cognitive decline specifically in MCI patients with elevated baseline homocysteine, not those with normal homocysteine. evidence_strength: strong, consensus: moderate [18].
• Regular vitamin C ≥1,000 mg/day modestly shortens colds, especially severe symptoms; prevention benefit is less clear. evidence_strength: moderate, consensus: moderate [30][26].
• B6 shows the most consistent inverse observational GI-cancer association among B-vitamins; dietary (not supplemental) folate is similarly protective. evidence_strength: moderate, consensus: mixed [32].
• Chronic high-dose zinc causes copper deficiency and cytopenia, risk rising with dose, age ≥70, female sex, CKD. evidence_strength: strong, consensus: moderate [36].

Emerging:

• Threshold-driven (non-linear) selenium biomarker models for Keshan disease prevention, favoring continuous moderate over short high-dose courses. evidence_strength: moderate, consensus: moderate [3].
• IV vitamin C as a radio/chemotherapy adjunct; a possible 3–4 day therapeutic window in sepsis. evidence_strength: strong (sepsis mortality meta-analysis) but explicitly hypothesis-generating; consensus: moderate [25][22].

Controversial:

• Net population effect of folic-acid fortification on cancer: dietary folate protective for GI cancers, supplements null, B12 possibly positively associated with esophageal adenocarcinoma. evidence_strength: moderate, consensus: mixed [32][10].
• Whether homocysteine is causal for cardiovascular disease or merely a marker, given lowering it doesn't reduce events. evidence_strength: strong (no CV benefit), consensus: mixed [8][37].

Unsupported / overstated:

• High-dose oral antioxidant vitamins prevent cancer in the general population — large trials have been disappointing. evidence_strength: moderate, consensus: moderate [22][29].
• "More selenium/zinc/iron is always better" — each has a documented toxicity syndrome that supplementation can precipitate in replete individuals [27][36][16].

6. Practical Clinical Applications

Targets and typical adult doses (verify against current formulary/guidelines before prescribing):

• Folate: RDA 400 µg DFE/day; pregnancy 600 µg DFE/day. Confirm B12 status before high-dose folate [1][21].
• B12: Oral high-dose (1,000–2,000 µg/day) or parenteral for malabsorptive deficiency; screen metformin, chronic PPI, bariatric-surgery, and vegan patients [1][20].
• Thiamine: 100–300 mg/day IV/oral for 5–10 days in refeeding-risk or alcohol-use-disorder patients, before or with glucose [23][15][2].
• Niacin: RDA 14–16 mg/day; pharmacologic doses (1–3 g/day) need hepatic/glycemic monitoring and add no CV outcome benefit over statins [22][14].
• B6: RDA 1.3–1.7 mg/day; avoid chronic dosing above ~100 mg/day (neuropathy risk) [11].
• Vitamin C: RDA 75–90 mg/day; ≥1,000 mg/day may shorten severe colds; watch oxalate stones at high chronic doses [26][30].
• Iron: Oral ferrous sulfate ~60 mg elemental, alternate-day dosing; IV iron for malabsorption, intolerance, or heart failure [24][17].
• Iodine: RDA 150 µg/day (250 µg pregnancy/lactation); avoid kelp supplements exceeding ATA's 500 µg/day advisory limit [33].
• Zinc: RDA ~8–11 mg/day; keep infection/diarrhea dosing short-course given copper-deficiency risk [1][36].
• Selenium: RDA 55 µg/day; do not supplement without documented deficiency (narrow window, SELECT harms) [27][3].
• Copper: Monitor in any patient on chronic high-dose zinc presenting with new cytopenia [36][19].

Key drug interactions: metformin and chronic PPI/H2-blocker therapy (B12); isoniazid (B6, niacin); high-dose folic acid masking B12 deficiency; amiodarone and iodinated contrast (iodine excess); zinc supplements interfering with copper and with certain antibiotic absorption.

7. Clinical Pearls

• Never supplement folate empirically without checking B12 — you may correct the anemia and let irreversible neurologic injury progress.
• Thiamine before dextrose, always, in any malnourished or alcohol-use-disorder patient.
• A homocysteine level that falls with B-vitamin therapy is a biomarker success, not a cardiovascular outcome — AIM-HIGH-style disappointment is the rule, not the exception, for surrogate-driven nutrient trials in this module.
• "Deficiency-driven" is the operative phrase for supplementation: SELECT (selenium) and zinc-induced copper deficiency both show that supplementing a nutrient-replete patient can cause net harm.
• New cytopenia in a patient on chronic zinc supplements (denture-cream users, high-dose OTC zinc) is copper deficiency until proven otherwise.

8. Common Misconceptions

• "Vitamin C megadoses prevent colds and cancer." Regular high-dose vitamin C modestly shortens severe cold duration but does not reliably prevent colds, and oral antioxidant trials for cancer prevention have been disappointing [30][22].
• "IV vitamin C is a proven sepsis therapy." Trial results are genuinely discordant (CITRIS-ALI positive on secondary endpoints, VITAMINS and ACTS negative); current evidence is explicitly labeled hypothesis-generating [25].
• "Natural supplements like kelp are a safe way to boost iodine." Kelp iodine content is highly variable and can easily exceed safe upper limits, precipitating thyroid dysfunction [33].
• "More zinc is always better for immunity." Chronic high-dose zinc causes copper deficiency and cytopenia; benefits are clearest only in documented deficiency or specific short-term therapeutic contexts (pediatric diarrhea) [1][36].
• "Lowering homocysteine with vitamins prevents heart attacks." It lowers a biomarker and reduces vascular stenosis but does not reduce cardiovascular events in trials [8].

9. Summary

Water-soluble vitamins and trace elements share a recurring logic: small body stores mean deficiency develops quickly, with distinctive signatures — megaloblastic anemia with subacute combined degeneration (B12), Wernicke-Korsakoff syndrome (thiamine), pellagra (niacin), scurvy (vitamin C), goiter (iodine), Keshan cardiomyopathy (selenium). Absorption physiology (intrinsic-factor loss, PPI/metformin effects on B12; hepcidin-mediated iron regulation) explains common etiologies and enables targeted, not shotgun, supplementation. Just as important is this module's cautionary throughline: high-dose niacin, selenium, and IV vitamin C each had compelling rationale that did not survive outcome trials (AIM-HIGH/HPS2-THRIVE, SELECT, discordant sepsis trials), and megadosing selenium, zinc, iron, or iodine causes its own toxicity syndromes. The task is to replace documented deficiency to a defined target and resist the frequently disproven assumption that more of a "good" nutrient is always better.

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. Understanding the Biological Evidence and Emerging Research Gaps in Nutrition That Impact the Health of School-Aged Children (BOND-KIDS). The Journal of Nutrition (2026). Review — trust 0.925.
2. Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association. Circulation (2026). Guideline — trust 0.917.
3. Current Advances in the Physiological Roles of the Thioredoxin-Like Family of Selenoproteins. Biological Trace Element Research (2026). Review — trust 0.917.
4. The Effect of Diet and Dietary Supplements on Iron Status of Active Females: A Systematic Review and Meta-analysis of Interventional Trials. Sports Medicine (2026). Systematic review — trust 0.912.
5. The association between serum trace elements and iron deficiency anemia in children and adolescents: a systematic review and meta-analysis. Hematology (2026). Systematic review — trust 0.842.
6. Overnutrition in mice impairs thyroid hormone biosynthesis and utilization, causing hypothyroidism, despite remarkable thyroidal adaptations. The Journal of Clinical Investigation (2026). RCT (preclinical) — trust 0.863.
7. Effects of Dietary Copper Deficiency on Colonic Barrier Integrity, Inflammatory Markers, and Gut Microbiota Composition in Mice. Nutrients (2026). Observational — trust 0.863.
8. Combined B-vitamin supplementation on homocysteine and vascular outcomes in coronary heart disease: a meta-analysis. Annals of Medicine (2026). Systematic review — trust 0.857.
9. Nutritional Status of Iodine and Association with Iron, Selenium, and Zinc in Population Studies: A Systematic Review and Meta-Analysis. Nutrients (2025). Systematic review — trust 0.842.
10. The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia. Leukemia (2026). Observational — trust 0.875.
11. Vitamin B6 nutrition, metabolism, and the relationship of diseases: current concepts and future research. Journal of Future Foods (2025). Review — trust 0.838.
12. Low Level of Selenium Predicts High Incidence of Colorectal Cancer. BMC Public Health (2026). Systematic review — trust 0.833.
13. Diet plays a supportive role in managing thyroid disorders – but a critical one! European Thyroid Journal (2026). Review — trust 0.833.
14. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. Journal of Applied Biomedicine (2026). Review — trust 0.833.
15. ESPEN guideline on clinical nutrition in the intensive care unit. Clinical Nutrition (2018). Guideline — trust 0.828.
16. Molecular mechanisms of iron metabolism and ferroptosis in cardiovascular diseases and intervention strategies targeting natural products. Molecular Medicine Reports (2026). Review — trust 0.825.
17. Bovine Lactoferrin Compared With Ferrous sulfate for Treating Iron-Deficiency Anemia in Bangladeshi Women — A Randomized Controlled Trial. The Journal of Nutrition (2026). RCT — trust 0.812.
18. Accelerated epigenetic aging as a modifier of homocysteine-associated cognitive decline: Findings from NHANES. Alzheimer's & Dementia (2026). Observational — trust 0.802.
19. Multifaceted Role of Copper Homeostasis in Gut Health: From Molecular Mechanisms to Therapeutic Interventions. Cells (2026). Review — trust 0.715.
20. Maternal vitamin B12, vitamin D, and folic acid status during pregnancy and child neurodevelopment: a systematic review. Frontiers in Neuroscience (2026). Systematic review — trust 0.775.
21. Preconception One-Carbon Metabolism Nutrient Levels in Preparing for Pregnancy Couples and Spontaneous Pregnancy Loss: A Prospective Cohort Study. MedComm (2026). Observational — trust 0.767.
22. NUTRITION INFORMATION BRIEFS - Niacin. Advances in Nutrition (2026). Review — trust 0.765.
23. The aftermath of alcohol misuse: Linking cellular damage, suboptimal micronutrient nutrition, and organ dysfunction. Pharmacology and Therapeutics (2026). Review — trust 0.765.
24. Iron Dysregulation and Vascular Diseases: A Contemporary Review. Journal of the American Heart Association (2026). Review — trust 0.765.
25. Mortality in septic patients treated with vitamin C: a systematic meta-analysis. Critical Care (2021). Systematic review — trust 0.757.
26. Are the UK's vitamin C recommendations evidence-based? A critical comment. British Journal of Nutrition (2025). Review — trust 0.733.
27. Selenium's Emergence from the Pool of Potentially Essential Trace Elements. Biological Trace Element Research (2026). Review — trust 0.725.
28. Phase III, randomized, single blind, comparative safety, and efficacy trial of intravenous iron isomaltoside (i3R) and ferric carboxymaltose in subjects with iron deficiency anaemia. Malaysian Journal of Pathology (2025). RCT — trust 0.725.
29. The Role of Diet and Specific Nutrients during the COVID-19 Pandemic: What Have We Learned over the Last Three Years? International Journal of Environmental Research and Public Health (2023). Review — trust 0.725.
30. Vitamin C reduces the severity of common colds: a meta-analysis. BMC Public Health (2023). Review — trust 0.695.
31. Reduced interleukin-2 production and increased CREMα protein expression in vegetarians and vegans due to zinc deficiency. Journal of Nutritional Biochemistry (2026). Observational — trust 0.752.
32. B vitamins intake and cancer risk: a structured narrative review of evidence on riboflavin, pyridoxine, cobalamin and folate. Pathology & Oncology Research (2026). Review — trust 0.700.
33. Iodine in Health and Disease: A Comprehensive Review. Nutrients (2026). Review — trust 0.695.
34. Homocysteine combined with multi-index screening for pregnancy complications: a narrative review. Frontiers in Endocrinology (2026). Review — trust 0.745.
35. The role of nutrition in prostate cancer risk, progression, and mortality: A comprehensive review. Clinical Nutrition ESPEN (2026). Review — trust 0.733.
36. Characterizing clinical patterns and associated factors of zinc-induced copper deficiency: Insights from large-scale pharmacovigilance databases. Clinical Nutrition ESPEN (2026). Observational — trust 0.637.
37. Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link? International Journal of Molecular Sciences (2021). Review — trust 0.593.
38. Vitamin B12 Deficiency in the Diagnostic Work-Up of Global Developmental Delay: A Treatable and Time-Sensitive Condition. Nutrients (2026). Review — trust 0.715. (B12 biomarkers: serum limitations, holotranscobalamin, methylmalonic acid.)
39. Position of the Academy of Nutrition and Dietetics: Vegetarian Diets. Journal of the Academy of Nutrition and Dietetics (2016). Guideline — trust 0.74. (B12 absorption via intrinsic factor and passive diffusion; supplementation.)
40. Controversial effects of metformin on human physiology and pathophysiology. Frontiers in Pharmacology (2026). Review — trust 0.637. (Metformin calcium-dependent ileal B12 malabsorption; MMA/myelin mechanism.)
41. Examining the Clinical Usefulness of Urine Methylmalonic Acid for Diagnosis of Vitamin B-12 Deficiency in Older Adults: A Pilot Study. Clinical Interventions in Aging (2026). Observational — trust 0.752. (High-dose B12 lowered urinary MMA and improved balance/cognition in older adults.)

Supporting sources also surfaced: Folate and global health review series, part 3 (Journal of Global Health 2026, review, trust 0.688); Homocysteine combined with multi-index screening for pregnancy complications (Frontiers in Endocrinology 2026, review, trust 0.745); Disorders Mimicking Wilson's Disease (Diagnostics 2026, review, trust 0.695); Modern challenges of iodine nutrition: vegan and vegetarian diets (Frontiers in Endocrinology 2025, review, trust 0.705); Phase III RCT of iron isomaltoside vs ferric carboxymaltose (Malaysian Journal of Pathology 2025, RCT, trust 0.725); The association between serum trace elements and iron deficiency anemia in children and adolescents (Hematology 2026, systematic review, trust 0.842); Impaired iron balance and erythrocytosis (Blood Cancer Journal 2026, review, trust 0.777).